Lead Product(s) : Undisclosed
Therapeutic Area : Rheumatology
Study Phase : Preclinical
Sponsor : Atlas Venture
Deal Size : $60.0 million
Deal Type : Series B Financing
GRO Bio gathers $60M series B to take gout rival to Krystexxa into clinic
Details : The Proceeds from the financing will be used to advance the Company’s lead program ProGly-Uricase into the clinic for the treatment of refractory gout and to broaden the GRObio pipeline.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 19, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Rheumatology
Highest Development Status : Preclinical
Sponsor : Atlas Venture
Deal Size : $60.0 million
Deal Type : Series B Financing
LOOKING FOR A SUPPLIER?